AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02328170 — intervention group
Intervention type: OTHER
Intervention: EUROIMMUN Allergy
Description: Immunoblot assay
Study NCT02328170 — intervention group
Intervention type: OTHER
Intervention: ImmunoCap
Description: Fluoroallergosorbent test
Study NCT01166074 — intervention group
Intervention type: BIOLOGICAL
Intervention: Subcutaneous IgG (SCIG)
Description: Administered according to normal clinical practice
Study NCT02395536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: office setting
Description: An office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not including ambulatory surgical centers
Study NCT02395536 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hosptial setting
Description: A hospital setting was defined as an operating room or electrophysiology lab inside the walls of a hospital.
Study NCT01140425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg tablet single dose
Study NCT03153319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Injection [Humira]
Description: Investigational Drug
Study NCT03153319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution for Injection
Description: Placebo Comparator
Study NCT01266642 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo HF-WBI
Study NCT01266642 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo CF-WBI
Study NCT01266642 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo HF-WBI
Study NCT01266642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01266642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01266642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01266642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02401269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01266642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01266642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01266642 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation
Description: Undergo HF-WBI
Study NCT02720666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.
Study NCT02185196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 20,000 IU vitamin D3 in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
Study NCT04126512 — intervention group
Intervention type: OTHER
Intervention: PDA ligation
Description: PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.
Study NCT00327704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albumin
Description: albumin 20% 100 ml/8 hours for 3 days
Study NCT00327704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline 100 ml/8hours for 3 days
Study NCT02410811 — intervention group
Intervention type: OTHER
Intervention: Cardiac magnetic resonance imaging (CMR)
Description: CMR is obtained on all participants in all arms/groups
Study NCT01266642 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Breast Irradiation
Description: Undergo CF-WBI
Study NCT04876482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transoral robotic surgery
Description: transoral robotic surgery (TORS) which remove the extra soft tissue of the base of the tongue and soft palate in this study
Study NCT04876482 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: oral appliance
Description: It is a kind of treatment for the participants who refuse surgeries and choose to use other kinds of conservative treatment. The conservative treatments included oral appliance, losing weights and using continuous positive airway pressure. The oral appliance would be wore only at night and it would press the soft palate and protrude the jaw.
Study NCT04876482 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: using continuous positive airway pressure
Description: The participants only used CPAP at night. The device composed of a main machine, pipe and mask. The participants would instruct to wore the mask. The main machine would give positive airway pressure to open the airway and avoid collapsing.
Study NCT04876482 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: losing weights
Description: The participants would ask to lose weight by changing their diets and exercising, without using drugs and surgeries.
Study NCT04876482 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: oropharyngeal rehabilitation
Description: OPR included exercise for soft palate, tongue and oropharynx. There are 13 movements in OPR. The movements would be teach by a physical therapist.
Study NCT00353366 — intervention group
Intervention type: BIOLOGICAL
Intervention: Rotarix
Description: Two doses of the oral vaccine
Study NCT00353366 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
Study NCT03296228 — intervention group
Intervention type: RADIATION
Intervention: Flexibility Radiographs (supine, supine side-bend, FB)
Description: Supine, supine side-bend, fulcrum bend
Study NCT01130077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A2 restricted glioma antigen peptides vaccine
Description: Vaccine given every 3 weeks
Study NCT01130077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Vaccine given every 3 weeks
Study NCT02141438 — intervention group
Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information.
Study NCT01970280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Study NCT01649999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral
Study NCT01649999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01568255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Ergocalciferol therapy at 50,000IU for 8 weeks
Study NCT01568255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo at 50,000IU for 8 weeks
Study NCT02837666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation with Spirulina maxima
Description: Supplementation with Spirulina maxima (4.5 g/d) in capsules during 6 weeks.
Study NCT03296228 — intervention group
Intervention type: RADIATION
Intervention: Flexibility Radiographs (awake traction)
Description: awake traction
Study NCT03296228 — intervention group
Intervention type: RADIATION
Intervention: Flexibility Radiographs (STUGA)
Description: supine traction under GA
Study NCT02453295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The IG will meet weekly for 2 hours for 8 weeks. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will be completed by phone at all timepoints. The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2 as well as a Workshop Evaluation 2 days following the final workshop (T2).
Study NCT01109316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro 2 day reservoir in-use
Description: Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
Study NCT01109316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro 6 day reservoir in-use
Description: Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
Study NCT01109316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart 6 day reservoir in-use
Description: Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
Study NCT02837666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Washout
Description: 2 weeks washout period to each study subject to avoid any possible carryover effect.
Study NCT02837666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation with placebo
Description: Supplementation with placebo (4.5 g/d) in capsules during 6 weeks.
Study NCT02837666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isoenergetic diet
Description: All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 14 weeks
Study NCT02837666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Participants are going to exercise five days a week with the following protocol: Between 5 and 10 min of heating exercise, Between 20-30 min anaerobic exercise and 20-30 min of aerobic exercise (cardiovascular exercise): walking, jogging, running and/or cycling, Three days a week aerobic intensities will be between 60% and 80% and two days between 70% and 90% of the maximum heart rate reserve, and five final minutes of stretching.
Study NCT03042338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CET: Central Executive Training
Description: CET: Central Executive Training
Study NCT03042338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CET: Comparison Executive Training
Description: CET: Comparison Executive Training
Study NCT01569074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 100mg twice daily for 12 weeks
Study NCT01569074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
Study NCT01569074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 75mg twice daily for 12 weeks
Study NCT01569074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 50mg twice daily for 12 weeks
Study NCT01569074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 12 weeks
Study NCT03459066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Institution-Group
Description: The study includes three measurement times:~* Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~* Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~* Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life.
Study NCT03521674 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: pregnancy termination
Description: Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done
Study NCT03623217 — intervention group
Intervention type: BEHAVIORAL
Intervention: Qualitative interviews with participants
Description: For the development and validation of a questionnaire.
Study NCT02374008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT02374008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT01087424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R mini CHOP
Description: Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
Study NCT03618797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-PIF cap.160/2mg + Placebo
Description: Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
Study NCT03618797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Livalo tab. 2mg + Placebo
Description: Pitavastatin ca 2mg
Study NCT02660918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
Study NCT02660918 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Equal volume injection of normal saline with the same paracervical technique
Study NCT03291912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chuna Manual Therapy
Description: * Unique manual therapy in traditional Korean medicine~* Mandatory techniques for neck part and selective techniques for other part (if necessary)~* Selective techniques depends on a patient's condition (judged by traditional Korean medicine doctor)
Study NCT03291912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Description: 1. Physical therapy based on traditional Korean medicine theory~   * Electrical stimulation: either Meridian muscle interferential current electricity or Meridian transcutaneous electricity~  * Heat stimulation: either Hot pack or Infrared lamp~2. Patient education~   * Physical and pathological explanation of cervicogenic dizziness~  * Cause and risk factors of cervicogenic dizziness~  * Functions of muscles related to cervicogenic dizziness~  * Home exercising to self-manage cervicogenic dizziness
Study NCT02185196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20,000 IU Miglyol-oil in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
Study NCT01003873 — intervention group
Intervention type: BIOLOGICAL
Intervention: Evaluation of the endocannabinoid system
Description: The evaluation of the endocannabinoid system consist in the determination of plasma concentration of the 2 main endocannabinoids (2AG and AEA) before (5 blood samples) and after (5 blood samples) after consumption of a calibrated food. As a comparator, ghrelin will be measured at the same time.
Study NCT01003873 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy of visceral and peripheral adipose tissue
Description: The endocannabinoids will be also determined in adipose tissue. Biopsy of visceral and peripheral adipose tissue will be done during surgery and peripheral adipose tissue will be done 6 months after surgery.
Study NCT01003873 — intervention group
Intervention type: BIOLOGICAL
Intervention: Evaluation of metabolic parameters
Description: The evaluation of the metabolic status consist in evaluation of body composition (DEXA), determination of visceral adiposity (CT scan) and measurement of plasma lipids, glucose, insulin, leptin, adiponectin.
Study NCT00616889 — intervention group
Intervention type: DRUG
Intervention: Seroquel
Description: The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.
Study NCT04984694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized virtual reality training programs group (Hot-Plus group)
Description: In this study, the investigators utilised interactive-video games called Xavix Hot Plus(Hot-plus, Shinsedai\[SSD\] Co. Ltd, Shiga Japan), which was designed specifically for rehabilitation and reported high participant motivation and enjoyment while playing.
Study NCT04984694 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social interaction group
Description: The social interaction group will get together as a group for social interaction one hour weekly for 12 weeks.
Study NCT01717729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
Study NCT01717729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
Study NCT01717729 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine
Description: The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev γ ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).
Study NCT01053169 — intervention group
Intervention type: BIOLOGICAL
Intervention: Beriplex® P/N
Description: Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
Study NCT01053169 — intervention group
Intervention type: BIOLOGICAL
Intervention: Fresh Frozen Plasma (FFP) and Beriplex® P/N
Description: FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
Study NCT01053169 — intervention group
Intervention type: OTHER
Intervention: Fresh Frozen Plasma
Description: Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
Study NCT01003873 — intervention group
Intervention type: BEHAVIORAL
Intervention: Evolution of behavioral parameters
Description: The behavioral evaluation will de done with different questionnaires: ORWELL 97, HAD scale, Three Factor Eating Questionnaire, Beck Depression inventory, Questionnaire of personality TCI.
Study NCT01003873 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dietician consultation
Description: The evaluation of the metabolic status will also be seen by a dietician.
Study NCT00798161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Description: BI 1356 high dose tablet, once daily
Study NCT00798161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 + metformin
Description: BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily
Study NCT01003873 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychologist consultation
Description: The behavioural evaluation will de done with a psychologist consultation
Study NCT02414958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Study NCT02414958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00798161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bi 1356 + metformin
Description: BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily
Study NCT00798161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg tablet, twice daily
Study NCT00798161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin 1000 mg tablet, twice daily
Study NCT00798161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: matching placebo
Study NCT03291912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: 1. Physical therapy based on traditional Korean medicine theory~   * Electrical stimulation: either Meridian muscle interferential current electricity or Meridian transcutaneous electricity~  * Heat stimulation: either Hot pack or Infrared lamp~2. Patient education~   * Physical and pathological explanation of cervicogenic dizziness~  * Cause and risk factors of cervicogenic dizziness~  * Functions of muscles related to cervicogenic dizziness~  * Home exercising to self-manage cervicogenic dizziness
Study NCT03996785 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking in Urban setting
Description: Walking for 60 minutes as described above
Study NCT03996785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking in nature setting
Description: Walking for 60 minutes as described above